Chief Business Officer
Dr. Newton has more than thirty years of experience in the biopharmaceutical and medical device industry. During his career he has held senior positions in finance, sales and marketing, business development and corporate strategy in the U.S., Europe and Asian markets.
Currently Dr. Newton is the Chief Business Officer for Trefoil Therapeutics, an early stage biopharmaceutical company that is developing an innovative new therapy for the treatment of uveitis, a serious autoimmune related inflammatory disease that is a leading cause of debilitating vison loss and blindness in younger people. He was previously the Vice President, Strategic Marketing & Business Development for Santen Pharmaceuticals, the leading ophthalmic pharmaceutical company in Japan. Prior to joining Santen, Dr. Newton was a principal at Louis Allen Worldwide where he consulted at the board and senior management level on organization change initiatives. He has also worked for Allergan, Inc. for more than twenty years where his final role was President of the Japanese subsidiary.
In the non-profit sector Dr. Newton was a board member and Chairman of OneOC, an organization that provides a broad range of services and resources to non-profit organizations.
Schalon holds a B.S. degree in Business Administration from California State University, Northridge, an M.B.A. from the University of California at Berkeley, and a doctorate in management from Case Western Reserve University.